Edge‑health patches market set to explode
The edge AI continuous vital‑signs patch market is projected to grow from $1.1B in 2026 to $6.3B by 2036 (≈18.9% CAGR), reflecting demand for always‑on, on‑device processing in healthcare and wellness. The growth mirrors industrial edge trends and signals cross‑sector opportunities for device+ML platforms. (openpr.com)
A Future Market Insights report dated March 17, 2026 places the sector at roughly $0.9 billion in 2025 and documents the dataset behind its 2026–2036 forecast. (futuremarketinsights.com)) BioIntelliSense secured FDA 510(k) clearance for its BioSticker and commercially launched a Data‑as‑a‑Service platform tied to a single‑use, 30‑day continuous monitoring form factor. (prnewswire.com)) Philips announced a strategic integration of BioIntelliSense’s on‑body sensor into its remote patient monitoring offering in July 2020, signaling large‑system OEM adoption of patch telemetry. (philips.com)) VitalConnect closed a $100 million financing round to accelerate commercialization of its VitalPatch ambulatory cardiac monitor, which carries FDA clearance and provides multi‑parameter real‑time vital‑sign telemetry. (medtechdive.com)) Biofourmis has expanded a device‑plus‑ML playbook through FDA‑cleared AI algorithms, a collaboration with GE HealthCare, an enterprise deal with AdventHealth, and the acquisition of Biovotion to integrate hardware and predictive analytics. (gehealthcare.com)) Silicon and tooling vendors are targeting the category: Ambiq has promoted ultra‑low‑power MCUs for on‑device health models at Medica 2024, and Nordic Semiconductor publishes an Edge AI Lab to simplify model deployment on wearable-class hardware. (wearable-technologies.com)) Market research firms note the category is bifurcating into a high‑volume wellness segment and a clinical, premium segment—driving parallel strategies for low‑cost disposable manufacturing and platform‑level AI services. (indexbox.io)) Incumbent patch providers show scale: iRhythm reported $591.8 million in revenue for full‑year 2024 and disclosed milestones including one million patients registered on its Zio continuous monitor. (investors.irhythmtech.com))
